Heparin-induced thrombocytopenia

Back to Top
Last updated on 2024-07-23:6 regimens on this page
6 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==ASH==
*2018: Cuker et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia link to PMC article EuroPMC
==BSH==
*2023: Arachchillage et al. Diagnosis and management of heparin-induced thrombocytopenia: Third edition EuroPMC
**2012: Watson et al. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition EuroPMC
**2006: Keeling et al. The management of heparin-induced thrombocytopenia EuroPMC
==NCCN==
*NCCN Guidelines - Cancer-Associated Venous Thromboembolic Disease
=Anticoagulation, all lines of therapy=
==Argatroban monotherapy==
===Regimen===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Lewis et al. 2001 (ARG-911) 	Not reported 	Prospective, historical control 	Multiple 	Reduced all-cause death, all-cause amputation, and new thrombosis
Lewis et al. 2003 (ARG-915) 	1996-11-01 to 1998-08-31 	Prospective, historical control 	Multiple 	Reduced all-cause death, all-cause amputation, or new thrombosis
Treschan et al. 2014 (ALicia)	Not reported to 2012-03-31	Randomized, double-blind 	Lepirudin 	Suggests less bleeding in surgical patients with argatroban.
Kang et al. 2014 	2005-02 to 2011-06 	Retrospective, propensity score-matched	Fondaparinux	Similar efficacy and safety to fondaparinux
Tardy-Poncet et al. 2015 	2009-09-10 to 2011-02-02 	Prospective 	None 	New or extended thrombosis in 25% of patients and major bleeding in 15%.
Note: In ALicia, only 15 patients (23%) in the study had confirmed HIT.
Note: In the study by Tardy-Poncet et al. only 20 patients were enrolled, 16 with confirmed by as judged by an independent scientific committee. The majority (14, 70%) were in an intensive care unit, and six patients died due to their underlying medical condition. 
====Anticoagulation====
*Argatroban (Acova) by the following study-specific criteria:
**ARG-911 & ARG-915: 2 mcg/kg/min IV adjusted to maintain activated partial thromboplastin time 1.5 to 3 times baseline value.
**ALicia, without liver dysfunction: 0.5 mcg/kg/min IV adjusted to maintain activated partial thromboplastin time 1.5 to 2 times baseline value.
**ALicia, with severe liver dysfunction (bilirubin >4 mg/dL): 0.25 mcg/kg/min IV adjusted to maintain activated partial thromboplastin time 1.5 to 2 times baseline value.
**Tardy-Poncet: Starting dose of 1 mcg/kg/min IV but those with hepatic impairment or at risk of decreased hepatic perfusion were recommended to start at 0.5 mcg/kg/min. Child-Pugh Class C patients were excluded.
One course
===References===
#ARG-911: Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang IK, Rifkin SD, Moran J, Hursting MJ, Kelton JG; ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001 Apr 10;103(14):1838-43. link to original article EuroPMC
#ARG-915: Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG; ARG-915 Study Investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;164:1849-1856. link to original article EuroPMC
#ALicia: Treschan TA, Schaefer MS, Geib J, Bahlmann A, Brezina T, Werner P, Golla E, Greinacher A, Pannen B, Kindgen-Milles D, Kienbaum P, Beiderlinden M. Argatroban versus lepirudin in critically ill patients (ALicia): a randomized controlled trial. Crit Care. 2014 Oct 25;18(5):588. link to original article link to PMC article EuroPMC NCT00798525
#Retrospective: Kang M, Alahmadi M, Sawh S, Kovacs MJ, Lazo-Langner A. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood. 2015 Feb 5;125(6):924-9. Epub 2014 Dec 16. link to original article EuroPMC
#Tardy-Poncet B, Nguyen P, Thiranos JC, Morange PE, Biron-Andreani C, Gruel Y, Morel J, Wynckel A, Grunebaum L, Villacorta-Torres J, Grosjean S, de Maistre E. Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial. Crit Care. 2015 Nov 11;19:396. link to original article link to PMC article EuroPMC
==Danaparoid monotherapy==
===Regimen===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Chong et al. 2001	Not reported in abstract	Phase 3 	Dextran 70 	Improved complete clinical recovery with danaparoid
Kang et al. 2014 	2005-02 to 2011-06 	Retrospective, propensity score-matched	Fondaparinux	Similar efficacy and safety to fondaparinux
Note: The full manuscript for Chong et al. 2001 was not available for review.
====Anticoagulation====
*Danaparoid (Orgaran) 2400 anti-Xa units IV bolus once on day 1, then 400 units/hr IV for 2 hours, then 300 units/hr IV for 2 hours, then 200 units/hr IV continuous infusion for 120 hours (total dose: 6200 units)
5-day course
===References===
#Chong BH, Gallus AS, Cade JF, Magnani H, Manoharan A, Oldmeadow M, Arthur C, Rickard K, Gallo J, Lloyd J, Seshadri P, Chesterman CN; Australian HIT Study Group. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study. Thromb Haemost. 2001 Nov;86(5):1170-5. link to original article EuroPMC
#Retrospective: Kang M, Alahmadi M, Sawh S, Kovacs MJ, Lazo-Langner A. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood. 2015 Feb 5;125(6):924-9. Epub 2014 Dec 16. link to original article EuroPMC
==Fondaparinux monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Kang et al. 2014	2005-02 to 2011-06 	Retrospective, propensity score-matched	1. Argatroban2. Danaparoid	Similar efficacy and safety to argatroban, danaparoid
====Anticoagulation====
*Fondaparinux (Arixtra)
===References===
#Retrospective: Kang M, Alahmadi M, Sawh S, Kovacs MJ, Lazo-Langner A. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood. 2015 Feb 5;125(6):924-9. Epub 2014 Dec 16. link to original article EuroPMC
==Lepirudin monotherapy==
===Regimen===
Study 	Dates of enrollment 	Evidence 	Comparator	Comparative Efficacy
Treschan et al. 2014 (ALicia)	Not reported to 2012-03-31	Randomized, double-blind	Argatroban	Suggests less bleeding in surgical patients with argatroban.
Note: Only 15 patients (23%) in the study had confirmed HIT.
====Anticoagulation====
*Lepirudin (Refludan) by the following renal function-based criteria:
**Continuous renal replacement therapy: 5 mcg/kg/hr IV continuous infusion, adjusted to maintain activated partial thromboplastin time 1.5 to 2 times baseline value
**Creatinine 1.3 mg/dl or more: 10 mcg/kg/hr IV continuous infusion, adjusted to maintain activated partial thromboplastin time 1.5 to 2 times baseline value
**Creatinine less than 1.3 mg/dl: 50 mcg/kg/hr IV continuous infusion, adjusted to maintain activated partial thromboplastin time 1.5 to 2 times baseline value
One course
===References===
#ALicia: Treschan TA, Schaefer MS, Geib J, Bahlmann A, Brezina T, Werner P, Golla E, Greinacher A, Pannen B, Kindgen-Milles D, Kienbaum P, Beiderlinden M. Argatroban versus lepirudin in critically ill patients (ALicia): a randomized controlled trial. Crit Care. 2014 Oct 25;18(5):588. link to original article link to PMC article EuroPMC NCT00798525
==Rivaroxaban monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Linkins et al. 2016 (McMaster 2012-02-09)	2013-01 to 2015-07 	Prospective cohort	None 	New thrombosis in one of the HIT patients (8.3%)
Note: In the first prospective study of DOACs in HIT by Linkins, 22 patients were enrolled with suspected HIT. The overall symptomatic recurrent VTE rate was 4.5% (1 patient out of 22), but only 12 of the patients were confirmed to have HIT. The thrombotic event rate among HIT-positive participants was 8.3%. The study was stopped early due to slow accrual but had enrolled the minimum required number of HIT patients.
====Anticoagulation====
*Rivaroxaban (Xarelto): 15 mg PO twice per day until platelet recovery (or until day 21 if acute thrombosis present at study entry), then 20 mg PO once per day until day 30
30-day course
===References===
#McMaster 2012-02-09: Linkins LA, Warkentin TE, Pai M, Shivakumar S, Manji RA, Wells PS, Wu C, Nazi I, Crowther MA. Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study. J Thromb Haemost. 2016 Jun;14(6):1206-10. Epub 2016 May 10. link to original article EuroPMC NCT01598168
##Update: Warkentin TE, Pai M, Linkins LA. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. Blood. 2017 Aug 31; 130:1104-1113. Epub 2017 Jun 23. link to original article EuroPMC
=Other Treatments, all lines of therapy=
==IVIG monotherapy==
===Regimen===
Study 	Evidence 	Efficacy
Frame et al. 1989 	First published report	First report of IVIg use in HIT
Winder et al. 1998 	Case series 	Three additional cases in the literature
Padmanabhan et al. 2017	Case series 	Three refractory cases with resolution of thrombocytopenia
Park et al. 2018 	Case series 	Two additional cases
Note: There is a growing interest in the use of intravenous immunoglobulin for difficult cases of heparin-induced thrombocytopenia. There are no prospective, randomized studies, but there is a growing body of scientific literature to support the rationale in certain select cases. Thus, IVIg is included on this page for reference. 
====Supportive therapy====
*Intravenous immunoglobulin (IVIG) 1 g/kg IV once per day for two days (Winder et al., Padmanabhan et al., and Park et al.)
**The case reported from 1989 used 0.4 gm/kg/d for three days. 
===References===
#Case report: Frame JN, Mulvey KP, Phares JC, Anderson MJ. Correction of severe heparin-associated thrombocytopenia with intravenous immunoglobulin. Ann Intern Med. 1989 Dec 1;111(11):946-7. link to original article EuroPMC
#Case series: Winder A, Shoenfeld Y, Hochman R, Keren G, Levy Y, Eldor A. High-dose intravenous gamma-globulins for heparin-induced thrombocytopenia: a prompt response. J Clin Immunol. 1998 Sep;18(5):330-4. link to original article EuroPMC
#Case series: Padmanabhan A, Jones CG, Pechauer SM, Curtis BR, Bougie DW, Irani MS, Bryant BJ, Alperin JB, Deloughery TG, Mulvey KP, Dhakal B, Wen R, Wang D, Aster RH. IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia. Chest. 2017 Sep;152(3):478-485. Epub 2017 Apr 17. link to original article link to PMC article EuroPMC
#Case series: Park BD, Kumar M, Nagalla S, De Simone N, Aster RH, Padmanabhan A, Sarode R, Rambally S. Intravenous immunoglobulin as an adjunct therapy in persisting heparin-induced thrombocytopenia. Transfus Apher Sci. 2018 Aug;57(4):561-565. Epub 2018 Jun 26. link to original article link to PMC article EuroPMC
Category:Heparin-induced thrombocytopenia regimens
Category:Disease-specific pages
Category:Autoimmune hematologic conditions
Category:Thrombotic disorders